High-sensitivity Troponin T is Detectable in Most Patients with Clinically Stable Heart Failure

Kristopher S Lyons; Gareth McKeeman; Gary E McVeigh; Mark T Harbinson

Disclosures

Br J Cardiol. 2014;21(1):33-36. 

In This Article

Materials and Methods

As part of a study assessing the effect of statin therapy on biomarkers of HF, we studied 32 outpatients with stable HF. Patients were recruited from heart failure clinics within the Belfast Health and Social Care Trust.

Inclusion criteria were:

  • diagnosis of HF with an ejection fraction <45% determined by non-invasive imaging (2D echocardiography, myocardial perfusion scintigraphy or cardiac magnetic resonance imaging [MRI]) within previous 18 months

  • receiving stable medical therapy for treatment of HF, including loop diuretics, angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), beta blockers and spironolactone, as tolerated

  • able to give informed consent and to attend for follow-up appointments

  • over 18 years of age.

Exclusion criteria were:

  • history of uncontrolled hypertension (blood pressure [BP] >140/90 mmHg)

  • receiving the thienopyridine derivative clopidogrel, due to inhibitory effect on platelet assays

  • abnormal liver function (defined as aspartate aminotransferase [AST] or alanine aminotransferase [ALT] >3 times upper limit of normal)

  • previously documented adverse reaction to statin therapy or hypersensitivity to simvastatin or any of the excipients

  • currently taking potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, HIV protease inhibitors, erythromycin, clarithromycin) or ciclosporin, gemfibrozil or >1 g/day niacin, due to statin interaction

  • females were excluded if they were pregnant or lactating.

  • HsTnT was analysed on the Roche Cobas E602 multi-channel analyser (Immunoassay E Module) at the Belfast HSC Trust laboratories.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....